74090Market Entry Strategy & Prototype for PopulationLeap™ in the Immuno-Oncology MarketClosedStudyInnovate UKWe all understand each other to be unique. It is of little surprise that diseases such as Corona Virus affect people differently. In controlled studies otherwise health and identically selected people also show markedly differing immune responses. Having platform technologies that can repeatedly clarify what is happening at the molecular level in the immune system is important not just to understanding which patients will have poor outcomes from viral infections, but also who will response well or poorly to modern cancer treatments which use the immune system to attack the cancer cells. Current state-of-the-art technologies have mostly focussed on using larger numbers of patients with the hopes of extracting out meaning from the complex number of underlying molecular events that are involved. However, all have suffered from high level of base-line patient-to-patient variability. Our innovation takes a fundamentally different approach to those above. The innovation uses data algorithms to enable clearer read-out from deep sampling studies and identify biomarkers. We have developed the innovation from concept, own completely, and have already used it to reveal previous unknown details of therapeutics' action in in vitro systems, and in clinical blood sample analysis through collaborative projects. The platform has been packaged into a collaborative offering called PopulationLeap(tm), and Trajecture is currently collaborating with several organisations to develop the technology, which has brought new insight into immune response with implications for immune-oncology trials and understanding how otherwise identical people have markedly different immune responses. We seek funding to develop our market entry strategy to the economic problem of targeting immuno-therapies in a market expected to be worth $125-130Bn by 2026\.